Phase 2 trial testing potential first-in-class Cushing’s treatment
Lundbeck has launched a Phase 2 clinical trial to assess the efficacy, safety, and tolerability of Lu AG13909, a potential first-in-class treatment for Cushing’s disease. “We are pleased to advance this new approach to potentially treating unmet needs in Cushing’s disease, a condition that, when uncontrolled, is debilitating…